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INTRODUCTION
Tuberculosis of the nervous system can present as tuberculous meningitis,
tuberculoma of brain, Potts paraplegia, tuberculosis of spine and rarely as arachnoidi-
tis and vasculitis.
Tuberculosis is conventionally treated for 12 to 18 months to ensure adequate cure,
stabilise quiescence and prevent relapses.With the introduction of rifampicin and
pyrazinamide it became feasible to shorten the duration of chemotherapy to 6 to 9
months. Many controlled clinical trials conducted all over the world have confirmed the
success of this approach in pulmonary tuberculosis by evolving 100% effective SCC
regimens1-5. In a few studies especially tuberculous lymphadenitis, tuberculous abdo-
men and pericarditis SCC has also been used and found to be as effective as conventional
regimens6,7. However, only recently has SCC been tried for neurotuberculosis. This
presentation briefly highlights some of the chemotherapy trials conducted at the
Tuberculosis Research Centre in some areas of CNS tuberculosis8-10.
What is SCC? SCC refers to chemotherapeutic regimens containing powerful
bactericidal drugs like INH, Rifampicin and Pyrazinamide, by the use of which the
duration of treatment of TB is reduced from the conventional 12 to 18 months to 6 to 9
months.
RATIONALE OF SCC :
The rationale for the use of short course chemotherapy is based on the different
microbial populations in tuberculous lesions and the anti-microbial activity of different
drug combinations for effective chemotherapy11,12.
MICROBIAL POPULATION
It is possible to differentiate at least 3 different types of bacterial population11,13.
The first is the population of organisms which actively grow at neutral pH in liquefied
caseous material that covers the cavity wall, mainly drug susceptible mixed with drug
resistant mutants. The second population is made up of organisms located in an acid pH
environment especially inside macrophages. The organisms coated with antibody inside
macrophage phagolysosomes presumably grow very slowly. The third population
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CHOICE OF DRUGS IN SCC12
SCC was made possible by the use of two drugs - Rifampicin and Pyrazinamide.
Rifampicin was found to be effective not only against actively multiplying organ-
isms but also against dormant or persisting organisms responsible for relapses after
treatment was stopped. With the rediscovery of pyrazinamide as a potent drug against
organisms located in an acid environment, especially inside macrophages it became
feasible to reach these difficult regions to kill the organisms. Isoniazid is very effective
againstrapidly multiplying extra cellular organisms. The combination of pyrazinamide
with rifampicin and isoniazid further increased the effectiveness of chemotherapy.
Likewise, regimens with rifampicin in combination with isoniazid and streptomycin
were almost 100% effective when given for 9 months. These findings led directly to the
recommendation by the British Thoracic Association4, American Thoracic Society14 and
others15 of 6 months short course chemotherapy for tuberculosis. Rifampicin and
pyrazinamide along with isoniazid are therefore the key sterilizing drugs in the
chemotherapy of tuberculosis with SCC.
RELAPSES IN TUBERCULOSIS :
With adequate chemotherapy one may get sputum conversion at the end of
treatment but culture becomes positive again after treatment is discontinued i.e. patient
has a bacteriological relapse. Studies have shown that the majority of the patients
relapse with organisms sensitive to the drugs used. With the advent of highly effective
chemotherapeutic regimens with practically 100% efficiency, bacteriological relapse has
become the most crucial factor in determining the relative merits of chemotherapeutic
regimens14.
To sum up, the aim in SCC is 1) to give a bactericidal drug combination in the initial
two months, which will be effective against sensitive and resistant mutants. Aim being
to achieve a rapid and total kill of the actively mutiplying bacterial population. 2) 
Sterilising drugs to prevent relapses. These act on slowly multiplying bacilli where there
are no resistant mutants.
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ADVANTAGES OF SCC :
1) Shortened duration, better compliance ;
2) Rapid conversion;
3) Risk of relapse less;
4) Acceptable level of toxicity; and
5) Cost effectiveness.
DOSAGE OF ANTI-TB DRUGS COMMONLY USED IN SCC :
Dosage Schedule *
Rhythm of
administration
Daily
Thriceweekly
Twiceweekly
INH Rif
mg mg
300 450
400 450
600 450
PZA Emb
(G) mg 
1.5 600
1.5 1000
2.0 1200
* For patients weighing 40 kgs.
Though most of the trials were related to pulmonary tuberculosis the available
data suggest that the approach could be extended to extra-pulmonary forms of the
disease without many changes.
TRC STUDIES IN NEUROTUBERCULOSIS :
Though isolated reports on SCC in CNS tuberculosis17 is ava lable there are not
many controlled clinical trials reported in neurotuberculosis. Encouraged by pulmonary
tuberculosis studies done in TRC, we have done studies in TB spine, Pott’s paraplegia,
brain tuberculoma, and tuberculous meningitis. In what follows we discuss the role of
SCC in TB spine, Pott’s paraplegia and brain tuberculoma. Tuberculous meningitis
studies are in progress and it is too early to draw any conclusions.
TUBERCULOSIS OF SPINE
Both medical and surgical approaches have been employed for the management of
TB spine. Surgical approaches include debridement surgery and radical surgery (Hong
Kong surgery) consisting of removal of diseased vertebrae and bridging of the gap with
autologous bone graft. Chemotherapy consisted of administering streptomycin, isoniazid
and PAS for 18 months with immobilisation in plaster shells. It was soon established that
chemotherapy alone was as effective as surgery and patient could be treated as out--
patients. In another study conducted in Hong Kong where all TB Spine patients
underwent radical surgery with 6 to 9 months of chemotherapy containing INH and
Rifampicin supplemented by Streptomycin twice a week, it was shown that short course
chemotherapy of 6 and 9 months duration was effective18.
Subsequent to this in the study at TRC, it was decided to compare short course
chemotherapy with and without radical surgery in patients with tuberculosis of spine.
Patients with clinically and radiographically active spinal tuberculosis involving the
bodies of the thoracic and/or lumbar vertebrae were eligible for admission provided they
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did nothave obvious paraplegia. The patientswere first assessed by the orthopaedic
surgeon. If  considered suitable for surgery, they were randomly allocated to one of the
following regimens:
a Chemotherapy with isoniazid 6 mg/kg plus rifampicin 10-15 mg/kg 
daily for 6 months with radical surgery (Rad 6 regimen - Surgery +
chemotherapy)
b Ambulatory chemotherapy with isoniazid plus rifampicin daily in the
same dosages as in (a) for 6 months (Amb 6 regimen - chemotherapy
alone for 6 months), and
C Ambulatory chemotherapy with isoniazid plus rifampicin daily in the
same dosages as in (a) for 9 months (Amb 9 regimen - chemotherapy
alone for 9 months)
In all 303 patients were admitted to the study and after excluding43 patientsfrom
main analysis 260 remained in final analysis, 85 in Rad 6 series, 83 in Amb 6 series and
92 in Amb 9 series.
PRE-TREATMENT CHARACTERISTICS
The distribution of the clinical, radiological and bacteriological findings before the
start of treatment was broadly similar for the 3 series.
TABLE 2 : PRE-TREATMENT CHARACTERISTICS
Pre-treatment Total
characteristics No. %
Total patients 260 100
Age 0- 4 35 13
(Years) 5 - 14 52 20
15 - 34 107 41
35 -54 57 22
55or more 9 3
Sinus and/or clinically-evident
Abscess
Kyphosis
Limitation of movement
Myelopathy (independentassessment)
Site of lesion
Thoracic
Thoraco-lumbar
Lumbar
Lumbo-sacral
Mediastinal Psoas
abscess shadow
51 20
219 84
246 95
19 7
97 37
35 13
110 42
19 7
149 57
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All patients in Rad 6 series were admitted as in-patients and 47 (60%) Amb 6 and
48 (52%) Amb 9 patients were also admitted. Out patients attended the centre twice a
week and were given that day’s doses under supervision and were supplied drugs for the
next 2 or 3 days for self-administration. The homes of children aged below 5 years were
visited daily and the drugs administered under supervision. The drug regularity was
very high 97% and identical in the 3 series.
Results Table 3
18 months I 36 months
Rad6  Amb6 Amb9 Rad6 A m b 6  A m b 9
% % % % % %
Favourable 58 58 60 80 87 96
Still not
favourable 33 36 38 9 7 3
Unfavourable* 9 6
Total patients 85 83 92
“Death / Myelopathy / Additional Treatment
At 18 months the status of 58% of the Rad 6, 58% of the Amb 6 and 60% of the Amb
9 patients was classified favourable, that is they had no sinus or clinical abscess present,
no myelopathy with functional impairment and had no additional operation or chemo-
therapy and no modification of allocated regimen; they also had no limitation of their
physical activity due to the spinal lesion and their disease was radiographically
quiescent. A further 28 (33%), 30 (36%) and 35 (38%) respectively had not yet attained
such a favourable status radiographically; the remaining 8 (9%), 5 (6%) and 2 (2%)
respectively were classified as unfavourable for reasons given in the table.
By 36 months 68 (80%), 72 (87%) and 88 (96%) of the 3 series respectively had
attained a favourable status. The results of the Amb 9 series being significantly better
than the Rad 6 series (p=0.003) but not the Amb 6 series (p=0.07).
CONCLUSION
The important conclusion from this study was that ambulatory chemotherapy
with SCC regimens based on isoniazid and rifampicin is highly successful in the
POTT’S PARAPLEGIA
Paraplegia used to be the most important serious complication of spinal tubercu-
losis and a fair proportion of beds in sanatoria and orthopaedic towards, were occupied
by patients who had Pott’s paraplegia. With the advent of effective chemotherapy and
early diagnosis of TB the number of cases of Pott’s paraplegia has come down. In order
to compare SCC with surgical procedures in the management of Pott’s Paraplegia a
controlled clinical trial was carried out by TRC.
The aim of the study was to assess the efficacy of multi-drug 9-month regimen with
or without surgery in the treatment of Pott’s paraplegia. Patients with clinical or
radiological evidence of active tuberculosis of vertebral bodies below D3 and paraplegia
of recent onset within one month were eligible for admission to this study.
Initially ten patients were treated with a 9 month regimen combined with radical
surgery within a week of starting treatment. The chemotherapy consisted of streptomy-
cin 0.75g plus isoniazid 300 mg plus rifampicin 12 mg/kg body-weight plus pyrazinamide
35mg/kg plus ethambutol 25 mg/kg daily for 2months, followed by rifampicin 12 mg/kg
plus isoniazid 15 mg/kg twice-weekly for the next 7 months (2RSHZEmb daily/2RHtw).
In the main study 25 patients were treated with one of the following three
regimens :
1. - CHEM series : Streptomycin 0.75g plus isoniazid 300 mg plus ethambutol 25 mg/
kg daily plus rifampicin 12mg/kg twice-weekly for 2 months, followed by ri-
fampicin 12 mg/kg plus isoniazid 15 mg/kg twice-weekly for the next 7 months
(2RtwSHEmb daily/7RHtw), or,
2. RAD Series : As in (1) and with radical excision of the diseased vertebrae, or
3. CT Series : As in (1) and with costotransversectomy
Combining the pilot study and the main study, 35 patients (17 RAD, 4 CT, 14
CHEM) were considered for the study. Of the total of 35 patients, 2(1RAD, 1CHEM) were
excluded (1(CHEM) died early in treatment: 1 (RAD) had no bony lesion on admission).
There remained 33 patients (16 RAD, 4 CT, 13 CHEM) for analysis.
Condition on admission : Of the 33 patients, 15 were males; 6 patients were aged
14 years or less and 16 were aged 35 years or more. The bladder was involved in 11 of
the 33 (33%). Sixteen (48%) patients had a chest X-ray lesion suggestive of pulmonary
tuberculosis but none had positive sputum by culture.
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Neurological examinations, : Neurological assessment was clinical. All patients
were assessed at start, then daily for 3 days, and thereafter, on alternate days till 2
weeks, weekly till 3 months, monthly till 9 months, 3-monthly till 3years and 6-monthly
thereafter. The surgery group patients were assessed, in addition, before the operation
and at 8 hours, 24 hours, and on the 2nd, 3rd, 5th and 7th days after the operation.
Management : Initially,all patients were hospitalised and the drugs were given
under the direct supervision of a staff member. After discharge from the hospital, the
patients collected the drugs once in 15 days as ambulant out-patients. The mean time
taken to become ambulant i.e. able to walk unaided was 128 days in the CHEM series
(range 25-367) and 85 days in the surgery series (range 9-122). The drug regularity was
very high. The coverage for the follow-up at the various time points ranged from 90-
 100%.
TABLE 4
Pat ients
Status No. %
Total patients 33 –
Non-tuberculous death 2 –
Patients with assessable response31 100
Paraplegia resolved 28 90
Unfavourable response * 3 10
* Rx extended beyond 9 months– 1
Death associated with spinal TB– 2
The table above gives the status at the end of 9 months of chemotherapyOf the
31 with an assessable response, 28 had resolution of paraplegia.
Speed of resolution: The speed of resolution with respect to motor power, spasticity
and bladder involvement, amalgamating the findings in the 3 regimens, is presented in
the table below. Considering motor power, 18 of 29 (62%) resolved by 3 months, 26 (90%)
by 6 months and 28 (97%) by 9 months. Regarding spasticity, 14 (48%) resolved by 6
months, 17 (59%) by 6 months, 17 59%) by 9 months and 21(72%) by 12 months. Bladder
recovery was complete in as manyas 6 patients by 3 months, and in all by 6 months.
TABLE 5
No. of Resolved by months
pts. 3 6 9 12
Bladder 9 6 9 9 9
Motor power 29 18 26 28 28
Spasticity 29 3 14 17 21
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CONCLUSION :
Of 29 patients alive at the end of treatment, all had their paraplegia resolved
completely with or’ without surgery.One died 11 months after treatment due to
myocardial infarction and two patients due to accidents at 54th month and 36th month.
The remaining patients were doing well at 60th month. There were no relapses. In this
study, the numbers are small and needs to be confirmed by a larger series. The present
study clearly demonstrates that Pott’s Paraplegia can be effectively treated using a SCC
regimen of 9 months duration. This finding has the same implications as that of the
treatment of TB spine using SCC in that the duration of treatment is drastically reduced
and the services of skilled neuro and orthopaedic surgeons may not be required.
BRAIN TUBERCULOMA
Brain tuberculoma is now being suspected much more often than in the past,
probably due to increased awareness of the disease among physicians and the greater
availability of the CT scan. Traditionally Brain Tuberculoma were treated by neurosur-
geons by biopsy, decompression or total removal. With the advent of anti-tuberculosis
drugs medical treatment of brain tuberculoma was established using combination
regimens which had to be administered for atleast 18 months. There are reports which
suggest that chemotherapy alone may be effective even for large brain tuberculomas with
increased intracranial tension; however, no reports are available on the use of short-
course chemotherapy for brain tuberculoma. A controlled study was undertaken to
evaluate the efficacy of short-course chemotherapy in the management of brain tubercu-
loma.
A circumscribed hyperdense lesion compared to the surrounding brain, with a
volume of 1000 cu.mm. or more, enhancing with contrast and having adjacent oedema
on CT scan, was taken as tuberculoma for admission to the study.
All cases admitted to the study were randomly allocated to one of the following 9-
month regimens:
Chemotherapy consisted of 3 drugs daily, rifampicin, isoniazid and pyrazinamide
for 3 months, in Regimen 1 and thrice-weekly in Regimen II, followed by 2 drugs,
rifampicin and isoniazid for 6 months, twice-weekly in both the regimens.
I
Regimen I : 3RHZ7/6RH2 (daily)
Regimen II : 3RHZ3/6RH2 (intermittent) I
The following investigations were done on admission: CT scan, radiographs of the
chest and skull, CSF culture, culture of sputum and urine, Mantoux, liver function tests
and haematological examinations. CT scan was repeated at 1 month, 2 months and every
2 months thereafter till 2 consecutive scans were normal. If the size of the mass at the
second month scan was more than 80% of the mass on admission, a biopsy of the mass
was done for histopathology and culture examinations.
In all, 144 patients (121 from General Hospital and 23 from the Railway Hospital)
were admitted to the study. The following analysis is based on 113 patients who have
completed treatment, after excluding 31 for various reasons, including 13 who were
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diagnosed as having a non-tuberculous lesion or where the scan criteria was not fulfilled,
and 5 who had chemotherapy terminated for serious toxicity in the first 3 months. Table
6 gives the characteristics on admission.
TABLE 6
Date on 3RHZ7/6RH2 3RHZ3/6RH2 Both
admission No. % No. % N O . %
Sex Male 23 40 21 38 44 39
Female 35 60 34 62 69 61
Age –15  21 36 28    51 49 43
(years) 15-24 16 28 15 27 31 27
35-44 7 12 4 7 17 10
–45  1 2 4 7 5 4
Lesion Single 43 74 45 82 88 78
Multiple 15 26 10 18 25 22
Mantoux 0-9 25 43 28 51 53 47
( m m ) 10-19 16 28 11 20 27 24
–20  11 19 11 20 22 19
Not tested 6 10 5 9 11 10
Total 58 100 55 100 113 100
Of a total of 113 patients, 58 were allocated to the daily regimen and 55 to the
intermittent regimen; 44 (39%) were males, 43% were less than 15 years of age, and only
4% wereabove the age of 44; and 88 (78%) patients had a single lesion in the CT scan.
The characteristics in the 2 regimens were similar.
TABLE 7
Svmptoms and signs Daily Intermittent Both
  No.  % No. % No. %
82  Convulsion 47 81 45 92 81
Headache 40 69 31 56 71 63
Vomiting 20 34 19 35 39 35
Limbweakness 21 36 13 24 34 30
Fever 13 22 11 20 24 21
77
Visual disturbances 14 24 12 22 26 23
Unsteady gait 8 14 6 11 14 12
Others 6 10 5 9 11 10
Normal 26 45 29 53 55 49
Papilloedema 11 19 9 16 20 18
Deficit 10 17 9 16 19 17
Papilloedema plus deficit11 19  8 15 19 17
Total patients 58 100 55 100 113 100
CLINICAL PRESENTATION :
Of the 113 patients, 20 presented with papilloedema only (Table 7), 19 had
papilioedema with neurological deficit, 19 had only neurological deficit and 55 had only
symptoms. Convulsion (81%) and headache (63%) were the main presenting symptoms
(Table 7); 35% complained of vomiting and 30% of limb weakness.
The initial chest radiograph was suggestive of pulmonary tuberculosis in 11. Of
these, 2 were culture-positive by sputum examination, with drug-sensitive organisms.
Table 8 shows the progress between 0 and 9 months as assessed by CT scan in 92
patients (45 daily, 47 intermittent) for whom readings were available. It was observed
that in both series taken together.
TABLE 8
Progress Daily Intermittent Both
(0-9 months) No. % No. % No. %
Lesion disappeared 36 77 34 7076 76
Lesion decreased
by > 50% 2 4 3 7 5 5
by < 50% 6   13 6 13 12 13
Static 2 4 0 0 2 2
Lesion increased
by > 50% 0 2 1 2 1 2
by < 50% 1 0 1
New lesion appeared 0 0 1 2 1 1
Total patients 47 100 45 100 92 100
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Tuberculomas had totally disappeared in 70 (76%) of the patients. In 17 (18%),
a decrease in the size of the lesion was observed. In 2 patients, the lesion remained static.
In 2 (2%) otherpatients, the lesions had increased in size and in another patient, a new
lesionhad appeared. Of the two patients with increased lesions, one refused surgery and
continued to have hemiparesis and papilloedema. The two patients whose lesions
remained static and the patient who had a new lesion were clinically doing well without
additional chemotherapy.
The patients are being followed up till 60 months, and the clinical status at 24
month for100 patients who have completed 24 months follow-up is given in table 9. Of
these,48 had no neurological deficit at the start of treatment and 52 patients had clinical
signs – 19with papilloedema plus deficit.At 24 months, 91 patients were normal
clinically;8 patients continued to have papilloedema and/or neurological deficit. None
of  the  .-patients had a relapse of tuberculoma.
TABLE 9
Clinical status Initial At 24 months
At the end of chemotherapy, the results with the daily and intermittent regimens
were similar.In all, 77% and 76%, respectively, showed total scan clearance. Clinically,
90% in the intermittent regimen and 91% in the daily regimen were normal. Residual
deficitwas seen in 6% in the intermittent regimen and 5% in the daily regimen. The
results of SCC of 9 months’ duration in thetrea mentof brain tuberculoma appear
encouraging from the available data; and suggest that SCC may become the treatment
of choice for brain tuberculoma. 
In the management of brain tuberculoma using SCC the following points need to
be kept in mind.
1. New lesions may appear and existing lesions may enlarge a phenomenon which
has been noticed in the management of other extra pulmonary TB lesions. e.g. TB
Lymphadenitis (Such events do not warrant any change in the management. (2) The role
of surgery is restricted to shunt surgery, biopsy and decompression following clinical
deterioration.
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Although scan deterioration at the end of two months was an indication for surgery
it was not resorted to unless there was concomittant clinical deterioration.
ADVERSE REACTIONS :
Jaundice was the most common adverse reaction seen, and was more common in
daily regimens and in those patients who underwent surgery. (TB spine 18% in RAD
series, 10% in AMB series,paraplegia 6% in RAD, 6% in CT series, Tuberculoma 22% in
daily and 5% in intermittent) The occurrence of jaundice does not warrant stoppage of
ATT. Effective management consists of stopping potentially hepatotoxic drugs like Rif,
PYZ and INH and replacing them with SM and ethambutol. Rif, INH & PYZ may be
reintroduced safely once jaundice has abated. Other less commonly encountered adverse
reactions include Arthralgia, ‘Flu syndrome’ and GIT disturbances which are easily
manageable using simple symptomatic drugs.
In Summary :
1. Short course chemotherapy of 6 to 9 months is an effective management schedule
for neuro tuberculosis.
2 Both children and adults can be treated with SCC.
3. The relapse rates after short course chemotherapy regimens vary from 0 to 7% in
pulmonary TB and almost nil in CNS TB showing the sterilising capacity of SCC
regimens.
4. Role of surgery is minimised or relegated to the background as shown in TB spine
and brain tuberculoma.
5. Jaundice is the most common side effect and this is clinically manageable.
6. Intermittent drug regimens are less toxic andas effective as daily regimens.
7. Patient’s compliance was not a problem in the above studies. So we can confidently
say that SCC has come to stay in the management of central nervous system
tuberculosis.
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